CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Toxicology drug testing (qualitative and quantitative) - Coverage Criteria

Coverage, documentation, and billing requirements for immunoassay (qualitative/presumptive) and definitive (quantitative/confirmatory) drug toxicology testing for Neighborhood Health Plan of Rhode Island across Medicaid (excluding EFP), Integrity, and Commercial lines.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyToxicology drug testing (qualitative and quantitative) - Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateJan 1, 2023

Next Review DateN/A

Key ActionVerify medical necessity, eligibility, coverage, and authorization prior to ordering quantitative or qualitative toxicology testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 unit/daydaily unit limit

80305-80307, G0480-G0483, G0659codes listed

Medicaid, INTEGRITY, Commercialplan lines

03/19/2025recent review

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Qualitative (Presumptive) Testing — Covered

Covered when ANY of the following are met:

Qualitative coverage conditions: A member is receiving treatment for chronic pain with prescription opioid or other medication associated with increased risk for misuse or addiction; OR a member is undergoing treatment for substance use disorder or otherwise requiring monitoring for use/misuse of controlled or illicit substances; OR misuse of prescribed or illicit substances is suspected; OR a member is beginning a pain management program or substance use disorder treatment program.

Qualitative tests may use urine, blood, or saliva specimens; urine is preferred for broad screening.

inv-02: Quantitative (Definitive/Confirmatory) Testing — Covered

Covered when ANY of the following are met:

Quantitative coverage conditions: Unexpected positive test inadequately explained by the patient; OR unexpected negative test (suspected medication diversion); OR need for quantitative levels to compare with established benchmarks for clinical decision making.

Quantitative testing must be ordered on an individual basis by the medical provider directly caring for the member at the time of order, must specify the drug to be confirmed, may not be from standing orders, and must be performed in a laboratory.

inv-15: Covered indications — Monitoring patients on chronic opioid or other high-risk medications; monitoring during SUD treatment; suspicion of misuse; initiation of pain management or SUD programs; unexpected/unexplained results requiring confirmation/quantification

Covered indications include, but are not limited to, the following clinical scenarios:

Covered indications: Monitoring patients on chronic opioid or other high-risk medications; monitoring during substance use disorder treatment; suspicion of misuse of prescribed or illicit substances; initiation of pain management or substance use disorder treatment programs; unexpected or unexplained test results requiring confirmation or quantification.

These indications apply to both qualitative (presumptive) and quantitative (definitive) testing as clinically appropriate.

This policy excludes coverage for testing performed for non‑medical purposes. Specifically, drug screening for medico‑legal (e.g., court‑ordered) or employment purposes is not covered. Additionally, specimen validity analyses performed as internal controls (for example, urinary pH, specific gravity, creatinine, oxidants, or other validity checks) are not separately billable and should not be reported as standalone services.

Additional constraints apply to routine and program‑related testing. The policy limits testing to one (1) unit per day, per test type (Qualitative or Quantitative), and it is not reasonable to perform simultaneous blood and urine testing for the same drug. Routine testing (for example, testing at every visit) and routine confirmatory testing when there is no unexpected result are not considered reasonable or necessary. Tests required as part of an all‑inclusive bundled substance use disorder (SUD) program or ordered solely to meet third‑party requirements are also ineligible for reimbursement. Qualitative tests are further restricted and may not be performed in Independent Clinical laboratories (POS 81) for Medicaid and Commercial lines of business.

Coding and Billing

Qualitative (presumptive) CPT codesCPTCovered

80305	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g. immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service.
80306	Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA)), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC-MS, LCMS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service.
80307	Drug test(s), presumptive, any number of drug classes, qualitative, any number of devices or procedures by instrument chemistry analyzers (e.g., utilizing immunoassay (e.g., EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA)), chromatography (e.g., GC, HPLC), and mass spectrometry either with or without chromatography, (e.g., DART, DESI, GC-MS, GC-MS/MS, LC-MS, LCMS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service.

Definitive (confirmatory) HCPCS codesHCPCSCovered

G0480	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem) and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods; qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 1-7 drug class(es).
G0481	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem) and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods; qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 8-14 drug class(es).
G0482	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem) and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods; qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 15-21 drug class(es).
G0483	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to, GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem) and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods; qualitative or quantitative, all sources(s), includes specimen validity testing, per day, 22 or more drug class(es).
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem), excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods, performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes.

inv-07: Daily unit limit — 1 unit per day per test type (Qualitative or Quantitative)

Daily unit limitTesting limited to 1 unit per day, per test type (Qualitative or Quantitative).

Simultaneous specimensNot reasonable/necessary to test for the same drug with both blood and urine specimens at the same time.

ApplicabilityLimit applies to each test type separately (i.e., one qualitative and one quantitative could each be billed up to 1 unit/day when medically indicated).

Provider Actions and Requirements

Prior Authorization

Prior Authorization & Medical Necessity

All services must be medically necessary to qualify for reimbursement. Providers are responsible for verifying eligibility, coverage and whether prior authorization is required before rendering services. Neighborhood may use NCDs, LCDs, InterQual, EOHHS recommendations, and Neighborhood Clinical Medical Policies to determine medical necessity. Contact Provider Services at 1-800-963-1001 for details.

Verify member eligibility, benefit coverage, and prior authorization requirements prior to service.
Neighborhood's Prior Authorization Reference page and Clinical Medical Policies provide plan-specific requirements.

Documentation Required

Clinical Sequencing: Qualitative First, Quantitative When Indicated

Qualitative (presumptive) testing should be performed first for routine monitoring or initial screening. Quantitative (definitive/confirmatory) testing is covered only when clinically indicated — for example, an unexpected positive or negative result, suspected diversion, or when quantitative levels are needed for clinical decision-making. Quantitative tests must be ordered for a specific drug by the medical provider directly caring for the member at the time of order (no standing orders) and must be performed in a laboratory.

Qualitative tests appropriate for chronic pain monitoring, substance use disorder treatment monitoring, suspected misuse, or initiation of pain/SUD programs.
Quantitative testing allowed for unexpected positive/negative results, suspected diversion, or when quantitative comparison to benchmarks is required.
Quantitative tests must be ordered individually with the specific drug indicated and cannot be blanket confirmatory panels or standing orders.

Denial Risk

Non‑Covered Scenarios That May Trigger Denial

The following scenarios are not covered and may result in claim denial: routine (per-visit) testing, testing required by third parties (employment, court-ordered), testing performed as part of an all-inclusive bundled substance use disorder program, tests ordered when qualitative testing is clinically sufficient, and simultaneous duplicate specimen testing (e.g., blood and urine for the same drug). Additionally, qualitative tests are not reimbursable from Independent Clinical Laboratories (POS 81) for Medicaid and Commercial lines.

Routine testing at every visit (qualitative or quantitative) is not covered.
Testing for employment, court, or other third-party requirements is not covered.
Testing included in an all-inclusive bundled SUD program is not separately reimbursable.
Quantitative testing when qualitative testing is clinically appropriate and sufficient is not covered.
Do not bill for testing the same drug simultaneously from blood and urine specimens.
Qualitative tests cannot be performed in an Independent Clinical Laboratory (POS 81) for Medicaid and Commercial lines of business.

Definitions

inv-13: Definition — Qualitative testing (immunoassay/presumptive/screening); specimen types and notes

DefinitionQualitative (presumptive/screening) testing detects the presence of a drug in a specimen using immunoassay or other screening methods (e.g., chromatography, chemical spot tests).

Specimen typesAcceptable specimens include urine, blood, or saliva (mouth swab), with urine preferred for broad screening due to a longer detection window.

Common methodsMethods include immunoassay (IA), chromatography, and spectrometry; qualitative tests are also called presumptive or screening tests.

inv-14: Definition — Quantitative testing (definitive/confirmatory); ordering specificity and lab requirements

DefinitionQuantitative (definitive/confirmatory) testing identifies and/or measures specific drugs and indicates presence or absence and quantity of a substance.

Ordering requirementsMust be ordered for a specific drug by the medical provider directly caring for the member at the time of order (no standing orders) and not as a comprehensive panel without a specific indication.

Laboratory requirementQuantitative/definitive tests must be performed in a laboratory.

OpenPayer

Toxicology drug testing (qualitative and quantitative) - Coverage Criteria

Coverage Criteria

Coding and Billing

Provider Actions and Requirements

Ordering Requirements

Not Covered

Definitions

Frequency Limits

Background

Revision History